Company Filing History:
Years Active: 2020
Title: The Innovative Journey of Dan Rosmarin
Introduction
Dan Rosmarin, a distinguished inventor based in Oxford, GB, has made significant contributions to the field of medical research through his innovative patents. With one key patent to his name, he focuses on enhancing patient safety and treatment efficacy, particularly concerning 5-fluorouracil toxicity.
Latest Patents
Dan’s most notable patent is titled "Method of determining risk of 5-fluorouracil toxicity." This invention provides an assay that is instrumental in predicting the risk of toxicity in subjects treated with 5-fluorouracil (FU). The method involves screening subjects for specific TYMS and DPYD polymorphisms, which are genetic variations associated with the response to FU. Identifying these polymorphisms helps in assessing the risk level for developing toxicity, enabling healthcare providers to make informed decisions about patient treatment plans.
Career Highlights
Dan Rosmarin has had a remarkable career, primarily associated with Oxford University Innovation Limited. His work at this organization has allowed him to translate his research findings into practical applications, directly benefiting patients by improving treatment personalization. His expertise and innovative mindset have positioned him as a key figure in the oncology research community.
Collaborations
Throughout his career, Dan has collaborated with notable colleagues such as David Kerr and Ian Tomlinson. These partnerships have fostered a productive research environment, leveraging collective insights to advance the understanding of cancer treatment and its complexities. Their combined expertise has undoubtedly contributed to the efficacy of Dan’s patent and its application in clinical settings.
Conclusion
Dan Rosmarin represents the essence of innovation in the medical field. His patented methods for assessing 5-fluorouracil toxicity risk illustrate the critical role of genetics in personalized medicine. As he continues to work with Oxford University Innovation Limited and collaborate with esteemed peers, Dan is set to influence the future of cancer treatment and improve clinical outcomes for patients worldwide.